secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001437749-25-034263
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Moleculin Biotech Enters Research Agreement with UNC to Evaluate Annamycin for Pancreatic Cancer
--------------------------------------------------------------------------------

- Agreement with University of North Carolina at Chapel Hill for investigator-initiated preclinical research on Annamycin for pancreatic cancer.
- Moleculin will supply Annamycin; studies will evaluate liposomal Annamycin vs. Doxil in PDAC GEMM models.
- CEO Walter Klemp noted Annamycin's high affinity for pancreas and correlation of topoisomerase II upregulation with poor survival.
- Preclinical research is grant-funded and dovetails with recently announced investigator-funded clinical trial in pancreatic cancer patients.
- Annamycin has Fast Track Status and Orphan Drug Designations from FDA for AML and STS lung mets, and EMA for relapsed/refractory AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/0001437749-25-034263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/mbrx20251110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer